| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $430K | -18.0% | -64.1% |
| SG&A Expense | $1.6M | -8.4% | -1.5% |
| Operating Income | -$2.0M | +10.6% | +28.2% |
| Net Income | -$2.0M | +11.3% | +29.4% |
| EPS (Basic) | -$1.23 | +34.9% | -623.5% |
| EPS (Diluted) | -$1.23 | +34.9% | -623.5% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Accounts Receivable | $40K | +0.0% | -58.7% |
| Total Assets | $6.1M | — | — |
| Current Liabilities | $2.5M | -4.8% | -25.6% |
| Total Liabilities | $2.5M | -4.8% | -25.6% |
| Stockholders' Equity | $3.6M | +2.0% | +36.5% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$5.6M | — | — |
| Financing Cash Flow | $7.8M | — | — |